Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular disease. How much one should or safely can lower this risk factor remains debated. We aimed to explore the relationship between progressively lower LDL-cholesterol concentrations achieved at 4 weeks and clinical eff...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) Vol. 390; no. 10106; pp. 1962 - 1971
Main Authors:	Giugliano, Robert P, Pedersen, Terje R, Park, Jeong-Gun, De Ferrari, Gaetano M, Gaciong, Zbigniew A, Ceska, Richard, Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose, Schiele, François, Mach, François, Ott, Brian R, Kanevsky, Estella, Pineda, Armando Lira, Somaratne, Ransi, Wasserman, Scott M, Keech, Anthony C, Sever, Peter S, Sabatine, Marc S
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 28.10.2017 Elsevier Limited
Subjects:	Adult Aged Aged, 80 and over Angina Antibodies, Monoclonal - therapeutic use Anticholesteremic Agents - therapeutic use Arteriosclerosis Atherosclerosis Cardiovascular disease Cardiovascular diseases Cerebral infarction Cholesterol Cholesterol, LDL - blood Cholesterol, LDL - drug effects Clinical trials Diabetes Double-Blind Method Drug therapy Effectiveness Female Follow-Up Studies Health risk assessment Heart attacks Humans Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Inhibitor drugs Kexin Laboratories Lipids Low density lipoprotein Male Middle Aged Monoclonal antibodies Myocardial infarction Patient Safety Patients Proprotein Convertase 9 - antagonists & inhibitors Proprotein convertases Risk Assessment Risk factors Safety Secondary analysis Statins Stroke Subtilisin Treatment Outcome Triglycerides
ISSN:	0140-6736, 1474-547X, 1474-547X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!